Marsha A Moses

This inventor holds 22 USPTO granted patents and 29 published patent applications, plus 3 CIPO patents and 3 EPO patents, primarily in Cancer Therapeutics. Top assignees: Children's Medical Center Corporation, Alseres Pharmaceuticals, Inc., Boston Life Sciences, Inc.. Active years: 1996-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marsha A Moses. Retrieved from https://idiyas.com/inventor/marsha-a-moses

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 29)

% Patents Active = 81.8

CIPO Patents = 3 (Patent Applications = 7)

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 3.0

ph-index = 9

Forward Citations = 210(Granted Patents)

Company Filing History:

20 out of 1,074

Children's Medical Center Corporation

patents

1 out of 6

Alseres Pharmaceuticals, Inc.

patents

1 out of 1

Boston Life Sciences, Inc.

patent

4. 1 out of 8,594

Massachusetts Institute of Technology

patents

5. 2 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1996-2025

Loading Chart...

Areas of Expertise:

Triple Negative Breast Cancer

Extracellular Vesicles

Engineered Liposomes

Fatty Liver Disease

Cyr61 Biomarker

Angiogenesis Inhibition

Antiangiogenic Peptides

Pharmaceutical Compositions

Troponin Subunits

Non-Invasive Screening

Tissue Remodeling

Cancer Diagnosis

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12383553 - Method for detecting or treating triple negative breast cancer (2025-08-12),

2. 12241888 - Platform for assessment of the transcytosis of extracellular vesicles across endothelial barriers and uses thereof (2025-03-04),

3. 11260132 - Engineered liposomes as cancer-targeted therapeutics (2022-03-01),

4. 7897591 - Method of treating fatty liver disease (2011-03-01),

5. 7858324 - Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin (2010-12-28),

6. 7452866 - Methods of inhibiting angiogenesis with fragments and homologs of troponin subunit 1 (2008-11-18),

7. 7432066 - Non-invasive enzyme screen for tissue remodeling associated conditions (2008-10-07),

8. 7393829 - Pharmaceutical compositions comprising fragments and homologs of troponin subunits (2008-07-01),

9. 7371812 - Antiangiogenic peptides (2008-05-13),

10. 7153660 - Non-invasive enzyme screen for tissue remodelling-associated conditions (2006-12-26),

11. 7078385 - Methods of inhibiting angiogenesis with fragments and homologs of troponin subunit I (2006-07-18),

12. 6811995 - Non-invasive enzyme screen for cancer (2004-11-02),

13. 6737507 - Antiangiogenic peptides and compositions thereof (2004-05-18),

14. 6653283 - Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis (2003-11-25),

15. 6589936 - Pharmaceutical compositions comprising recombinant troponin subunits (2003-07-08),

Sure, here is the article about inventor Marsha A. Moses:

Title: Innovator Spotlight: Marsha A. Moses - Pioneering Cancer-Targeted Therapeutics and Fatty Liver Disease Treatments

Introduction:

Marsha A. Moses, a distinguished inventor hailing from Brookline, Massachusetts, has made significant contributions to the fields of oncology and gastroenterology with his groundbreaking patents. With a portfolio of 20 patents to his name, Marsha A. Moses continues to push the boundaries of innovation in the medical field.

Latest Patents:

1. Engineered Liposomes as Cancer-Targeted Therapeutics: Marsha A. Moses’ groundbreaking patent introduces liposomes, specifically cancer-targeting liposomes, with ligands such as EGFR ligands and ICAM-1 ligands conjugated to liposome surfaces. This innovation revolutionizes targeted cancer therapy by optimizing the molecular ratio of different ligands to correspond with overexpressed proteins on the surface of cancer cells.

2. Method of Treating Fatty Liver Disease: Another remarkable patent by Marsha A. Moses focuses on treating fatty liver diseases using matrix metalloproteinase (MMP) inhibitors. This method offers a novel approach to managing various fatty liver disorders, including NAFLD, NASH, ALD, and more, by administering MMP inhibitors like Marimastat and other specified compounds.

Career Highlights:

Marsha A. Moses has showcased his expertise and passion for innovation through his tenure at esteemed institutions. He has notably worked at Children's Medical Center Corporation, where he spearheaded groundbreaking research and development projects that have shaped the future of medical interventions.

Collaborations:

Throughout his illustrious career, Marsha A. Moses has collaborated with visionaries in the field, including notable coworkers Dmitri G. Wiederschain and Robert S. Langer. These collaborations have fostered a dynamic environment for innovation and resulted in significant advancements in medical technologies.

Conclusion:

Marsha A. Moses stands as a trailblazing inventor whose relentless pursuit of excellence has led to transformative advancements in cancer-targeted therapeutics and fatty liver disease treatments. His innovative approach and collaborative spirit continue to inspire the next generation of inventors and pave the way for a brighter future in medical innovation.

If you need more information or have any specific requests, feel free to ask!

Profile summary based on public USPTO records.